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Using a variety of peptide analogues of oxytocin (OT) and Arg*-vasopressin (AVP), OT-mediated induction of urokinase-type plasminogen activator 
(uPA) was examined in LLC-PK, renal epithelial cells, which possess distinct high-affinity receptors of both the OT- and vasopressin renal (V2-) 
types. OT or OT-receptor specific agonists induced concentration-dependent CAMP synthesis, activation of the CAMP-dependent protein kinase 
(CAMP-PK) and uPA production consistent with their respective binding affinities for the V?- and not the OT-receptor. OT-mediated uPA induction 
could be inhibited in a concentration-dependent fashion by coincubation with a V>/V,-receptor specific antagonist, but not by an OT-receptor 
specific antagonist. Results implied that stimulation of CAMP- and uPA responses in LLC-PK, cells by OT was Vz-receptor-mediated. 
Neurohypophyseal nonapeptide hormone; Specific antagonist; Vasopressin V,-receptor; Urokinase-type plasminogen activator 
1. INTRODUCTION 
The specific binding of the neurohypophyseal nona- 
peptide oxytocin (OT) to high-affinity receptors in
myometrium [l-3] leads to inositol-trisphosphate turn- 
over and Ca’+ influx [4,5], responses which are similar 
to those induced by the binding of the other neurohy- 
pophyseal nonapeptide, vasopressin, to the hepatic 
vasopressin V,-receptor [6,7]. Interestingly, OT can 
have either diuretic or antidiuretic osmoregulatory ef- 
fects depending on the presence or absence of vaso- 
pressin [8-lo], which may be explained by the ability of 
OT to bind to the adenylate cyclase (AC)-stimulating 
vasopressin renal V,-type receptor present on distal tu- 
bules and collecting ducts [9,10]. OT has also been re- 
ported to enhance glomerular filtration rate [8] and to 
have a natriuretic effect [8,9], both of which are OT- 
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Abbrevtatlons. CAMP-PK. CAMP-dependent protein kinase or 
ATP:protein phosphotransferase (EC 2.7.1.37); AC. adenylate cyclase 
or ATP pyrophosphatelyase (cyclicizing, EC 4.6.1.1); AVP, Arg*- 
vasopressin; OT, oxytocin; uPA, urokinase-type plasminogen activa- 
tor (EC 3.4.21.31); IBMX, I-isobutyl-3-methylxanthine. 
specific [8]. Stimulation of glomerular filtration is prob- 
ably mediated by OT-receptors in the macula densa [I 11. 
The LLC-PK, renal epithelial cell line has been re- 
ported to possess low density high-affinity OT-receptors 
[ 12,131, in addition to V,-receptors (about 45,00O/cell) 
[14], which couple to AC stimulation [ 14,151, activation 
of the CAMP-dependent protein kinase (CAMP-PK) 
[14-161, and production of the extracellularly secreted 
protease urokinase-type plasminogen activator (uPA) 
[ 14,15,17]. In addition to agents elevating intracellular 
CAMP, phorbol esters stimulate LLC-PK, cells to pro- 
duce uPA by a CAMP-independent Ca”/phospholipid- 
dependent protein kinase (PK-C)-mediated pathway 
[14,18-211. 
We were interested in the second messenger pathway 
of OT-mediated uPA induction in LLC-PK, cells. We 
show here that OT is capable of stimulating CAMP 
synthesis, CAMP-PK activation and uPA induction in 
LLC-PK, cells. All of these responses, however, appear 
to be mediated by OT-binding to the V,-receptor. 
2. MATERIALS AND METHODS 
2.1. Muterials 
S-y-[“PIATP, [‘H]Arg*-vasopressin (AVP) and [3H]OT were from 
Amersham, and phosphocellulose paper (P-81) from Whatman. The 
OT and AVP analogues used, listed in Table I. were synthesized as 
described [3.22-251. Other materials were from previously described 
sources [14.26]. 
2.2. Cell culture 
Cells of the LLC-PK, pig kidney epithelial cell line [27] and the 
Vz-receptor deficient mutant Ml8 [14] were cultured as described 
previously [14.26]. 
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1. (A) Concentration dependence of uPA production by LLC-PK, cells in response to OT and AVP analogues. Cell monolayers were washed 
msively and then incubated for 8 h with agonists in serum-free DMEM as indicated: 0 (oxytocin), SO (dSOT), V (AVP), sV (SAVP), na (no 
ition), and the numbers represent he molar concentrations in negative log form. Medium (5 ~1) was spotted onto the casein-plasminogen agar, 
, after incubation at 37’C for 2-3 h, UPA activity became visible as zones of lysis in the agar. (B) UPA production by cells of the LLC-PK, 
V,-receptor deficient mutant Ml8 ccl1 lines in response to OT and AVP analogues. Cell monolayers of the LLC-PK, and Ml8 (18) cell lines 
were treated as in Fig. 1A. 
2.3. Enzyme assays 
Extracts for the assay of CAMP-PK catalytic activity were prepared 
and assayed as previously, using Kemptide (L-R-R-A-S-A-G) as sub- 
strate [14,26]. The CAMP-PK activity ratio expresses the C-subunit 
activity present in cell extracts (assayed in the absence of CAMP) 
relative to the total stimulatable activity (assayed in the presence of 
CAMP) [14,26]. The ratio estimates the extent of CAMP-PK activation 
induced by different agents elevating intracellular CAMP levels 
[26,28,29]. uPA activity was detected using the previously described 
spot test [30,3 11, with activity indicated by zones of proteolytic learing 
in the casein, due to plasmin activation. No proteolytic activity was 
observed in the absence of plasminogen. Protein was estimated using 
the dye binding assay of Bradford [32] with BSA (fatty-acid-free) as 
standard. 
2.4. CAMP determination 
Cells were treated with hormones and other agonists for 8 h as 
previously described [33]. Medium samples were then treated as de- 
scribed [25,26], and CAMP determined using the competitive protein 
binding assay of Tovey et al. [34]. 
2.5. Receptor binding 
Vasopressin and oxytocin binding by EDTA-suspended cells was 
measured at 30°C as described [14,35]. Dissociation constants (K,), 
the concentration of hormone corresponding to 50% maximal binding, 
were determined from competition binding experiments [3,14,23]. 
3. RESULTS 
Maximal specific [3H]AVP and [3H]OT binding ( 10m8 
M ligand) by LLC-PK, cells was 223 k 24 (n = 4) and 
Table I 
Dissociation constants of the neurohypophyseal structural analogues 
used in this study for [‘H]AVP and [‘HJOT in LLC-PK, cells 
Peptide/description [reference] Kn for binding 
sites+ (nM) for: 
[‘HIAVP [‘H]OT 
[Arg’lvasopressin (AVP) 1.4 f 0.6 4.6 
Oxytocin (OT) 776 2.8 + 0.4 
[Mpa’,Sar’]OT (dSOT)/OT-agonist [3,22] 820 4.5 + 0.4 
lThr4,Sar’]OT (TSOT)/OT-agonist [3] >103 ND* 
[Sar’]AVP (SAVP)N,-agonist [23] 3.6 f 0.9 78 
[Mpa’,Va14,Sar7]AVP (dVSAVP)/ 
V,-agonist [22] ND* ND* 
[Mca’,MeAla’]AVP (MMAVP)/ 
VJOT-antagonist [23] 101 ND* 
[Mca’,D-Phe’,Sar’]AVP (MFSAVP)/ 
V,/OT-antagonist [23,24] 52 f 8 4.4 f 1.0 
[Mca’,D-Phe2,11e4,Lys~AVP (MFIKAVP)/ 
V,N,-antagonist [25] ND* ND* 
[Mca’,Sar’,Om’]OT (MSOOT)/OT-antagonist” 6,510 40 
‘K,, was determined from competition binding studies with [‘HIAVP 
and [‘H]OT as described [23-251, using affinity constants (Scatchard 
analysis) for [‘HIAVP and [‘H]OT in LLC-PK, cells of 3.5 [14] and 
1.9 [12], respectively. Results represent he mean from at least two 
separate xperiments (n = 3 where S.D. is indicated). 
*Not determined. 
a Inhibitory activity in rat uterus in vitro: pA, = 7.34 (Mg*+-free me- 
dium); a detailed description of the synthesis and pharmacological 
properties of this OT-antagonist will be published elsewhere. 
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Fig. 2. UPA production by LLC-PK, cells stimulated by OT or dSOT 
in the absence (na) or presence of OT- (0), V,N,- (V2) or V,/OT- (Vl) 
specific antagonists. Cell monolayers were treated as in the legend to 
Fig. lA,B, in the presence of differing concentrations (designated as 
per Fig. IA,B) of the antagonists MAAVP (Vl), MFIKAVP (V2) or 
MSOOT (0). 
34 f 8.5 (n = 4) fmollmg respectively. Binding was 
further characterized by competition with the various 
AVP and OT analogues listed in Table I. The dissocia- 
tion constants (Kn) calculated from the displacement 
binding curves (not shown) are also listed. Reduced 
competition of [3H]AVP binding was exhibited by OT, 
OT-receptor and V,-specific ligands (15 to l&000-fold 
difference in &), compared to the V,-specific agonists 
SAVP and dVSAVP (Table I, and not shown). This 
implied that i3H]AVP binds predominantly to the V,- 
receptor of LLC-PI& cells. 
r3HjOT binding could be competed quite well by OT- 
and V,-specific ligands compared to the V,-agonist 
SAVP (about a 20-fold difference in Kn, Table I). AVP, 
however, also competed reasonably well for r3H]OT- 
binding sites (& of 4.6 nM compared to 2.8 nM for OT 
itself), implying that the OT-receptor of LLC-PI& cells 
can bind AVP, consistent with similar observations for 
OT-receptors from other tissues [3,36,37]. In conclu- 
sion, the V,-receptor accounted for about 95% of the 
specific [31-I]AVP binding at lo-* M ligand (less than 5% 
of the binding likely to be due to binding to the OT- 
receptor); whilst the OT-receptor accounted for about 
99% of the specific rH]OT binding at lo-* M OT (Table 
I, and not shown). 
3.1. CAMP production and CAMP-PK activation in 
LLC-PK, cells in response to OT 
We tested the analogues from Table I for the stimula- 
tion of CAMP production and CAMP-PK activation in 
LLC-PK, cells (Table IIA,B). Results for the non-recep- 
tor-media~d AC-activator forskolin are shown for 
comparison. Whilst even high con~ntrations of the OT- 
agonists dSOT and TSOT only very weakly stimulated 
CAMP synthesis (Table IIA, and not shown) and 
CAMP-PK activation (Table IIB, and not shown), high 
concentrations of OT induced marked responses. 
Whereas half-maximal responses were elicited at about 
10e7 M OT (Table IIA,B, and not shown) 1121, half- 
maximal CAMP production and CAMP-PK activation 
in response to AVP are at about lo-’ M (Table IIA,B) 
[12,37,38]. The V,-specific agonists dVSAVP and SAVP 
showed similar &s (Table IIA,B, and not shown) 1251. 
Thus, although OT and to a minor extent OT-specific 
agonists were capable of inducing CAMP-mediated re- 
sponses, the concentration-dependence of the responses 
was consistent with their respective affinities for the 
V,-receptor of LLC-PK, cells. In contrast, half-maxi- 
mal response in terms of Ca2’ influx occurs at about 5 
x lo-’ M OT in LLC-PK, cells [12]. 
3.2. uPA induction in LLC-PK, cells by OT and OT- 
spec$k agonists 
The above results were elaborated by testing the var- 
ious analogues for the stimulation of uPA-production 
in LLC-PK, cells. uPA activity was detected by spotting 
8h conditioned media onto a casein plasminogen agar, 
and incubating at 37°C [30,31], activity being indicated 
by zones of plasminogen-dependent proteolytic clearing 
in the agar (Fig. 1). Results (not shown) could be con- 
firmed using a calorimetric assay with the synthetic pep- 
tide substrate S-2251 [14,19,20,26]. OT and dSOT stim- 
ulated uPA production (Fig. 1A) but only at concentra- 
tions about 100 times higher than those for maximal 
induction by AVP and SAVP, consistent with the affin- 
ity of the respective ligands for the V,-receptor of LLC- 
PK, cells. 
Treatment of the V,-receptor deficient mutant Ml8 
1141 resulted in no uPA production (Fig. lB), supporting 
the conclusion that OT-stimulated induction of LLC- 
PK, cells was V,-receptor mediated. Further evidence 
was provided by coincubating lo-’ M AVP or SAVP 
(not shown) or 10m7 M OT or dSOT (Fig. 2) with vari- 
ous concentrations of OT-, V,/OT-, or V,N,-specific 
antagonists. Whilst the OT-antagonist MSOOT failed 
to block OT- or dSOT-mediated UPA induction, the 
V,N,-specific antagonist MFIKAVP inhibited uPA in- 
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duction in a concentration-dependent manner (Fig. 2). 
These results were consistent with OT- and OT-specific 
agonist uPA induction in LLC-PK, cells being V,-medi- 
ated. 
4. DISCUSSION 
The results here show that OT as well as OT-specific 
agonists can stimulate CAMP synthesis, CAMP-PK acti- 
vation and uPA induction in LLC-PK, cells. The con- 
Table HA 
Extracellular CAMP production induced by V,- and OT-specific 
agonists and antagonists in LLC-PK, and Ml8 cells 
Treatment* Extracellular CAMP production (pmol/lO” cells)’ 
LLC-PK, Ml8 
-1BMX +IBMX -1BMX +IBMX 
No addition 21 116 15 59 
50 PM forskolin 210 4,560 236 3,740 
1O-8 M AVP 380 8,830 14 141 
10-s M dVSAVP 282 6,010 14 112 
lo-’ M OT 38 555 11 52 
lo-’ M dSOT 23 112 13 50 
*Cell monolayers were treated for 8 h in serum-free DMEM in the 
absence or presence of 500 PM IBMX as indicated. 
‘Medium CAMP was determined as described in section 2, and is 
expressed per lo6 cells. Data represent the mean from a smgle typical 
experiment where the S.D. was less than 22% the value of the mean. 
Table IIB 
CAMP-PK activation in LLC-PK, cells induced by forskolin, V,- and 
OT-specific agonists and V,/OT- and OT-specific antagonists 
Treatment* CAMP-PK activity ratio 
-1BMX +IBMX 
No addition 
50 PM forskohn 
lo-’ M AVP 
10-s M AVP 
1O-9 M AVP 
1O-6 M OT 
lo-’ M OT 
lo-’ M OT 
1O-6 M dSOT 
lo-’ M dSOT 
1O-6 M TSOT 
lo-’ M TSOT 
10-s M SAVP 
1O-6 M MAAVP 
0.02 ? 0.01 0.14 f 0.04 (6) 
0.20 f 0.04 0.63 + 0.02 
0.18 + 0.05 0.82 f 0.07 (3) 
0.11 + 0.01 0.58 f 0.05 (3) 
0.07 f 0.01 0.36 f. 0.06 (3) 
0.07 f 0.02 0.51 f 0.05 (3) 
0.05 f 0.02 0.29 f 0.12 (3) 
0.03 f 0.01 0.05 f 0.01 (3) 
0.03 f 0.01 0.18 + 0.02 
0.03 + 0.01 0.05 f 0.01 
0.06 f 0.01 0.16 f 0.02 
0.02 f 0.01 0.07 + 0.01 
0.08 f 0.01 0.64 f 0.06 
0.04 + 0.01 0.08 f 0.01 
*Cell monolayers were treated for 30 min in serum-free DMEM in the 
absence or presence of 500 PM IBMX as indicated, prior to washing 
and preparation of cell extracts. Extracts were then assayed in the 
presence or absence of exogenously added CAMP (10 PM). Data 
represent he mean f S.D. (n in parentheses where n > 2). Total 
CAMP-PK activity (assayed in the presence of 10pM CAMP) was 2.8 
f 0.2 U/mg. 
centration dependence of the responses, the lack of OT- 
response of the V,-deficient LLC-PK, mutant M 18, and 
the inhibition of OT-mediated uPA induction by an 
V,N,-receptor specific, but not OT-receptor specific an- 
tagonist, strongly indicate that these responses are all 
mediated by binding of the respective ligands to the V2-, 
and not to the OT-receptor of LLC-PK, cells. Although 
activation of the Ca”-phospholipid dependent kinase 
(PK-C) by phorbol esters has been shown to stimulate 
uPA production in LLC-PK, cells independently of 
CAMP and CAMP-PK [14,18-211, binding of OT to the 
OT-receptor does not appear to lead to significant in- 
duction of uPA synthesis, at least within 8 h, as shown 
here. PK-C activation would accordingly not seem to 
couple to stimulation of the OT-receptor in LLC-PK, 
cells. Further investigations using specific OT-agonists 
and antagonists hould assist in elaborating the precise 
events of signal transduction following OT-stimulation. 
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